Rate My Professor Danny McAuley

His research specializes in ARDS, encompassing investigation of novel therapeutic agents such as mesenchymal stem cells, statins, extracorporeal carbon dioxide removal, aspirin, oncostatin M, and anti-microbial peptides through in vitro, in vivo human models, and phase 2 clinical trials. He pioneered patient stratification strategies in ARDS and explores sepsis diagnostics, delirium in critical illness, nosocomial infections, and interventions to improve recovery from critical illness. Professor McAuley has led high-impact international trials, including REALIST-COVID assessing mesenchymal stem cells in COVID-19 ARDS and RECOVERY-Respiratory Support. Notable publications include 'Development and validation of parsimonious algorithms to classify phenotypes of acute respiratory distress syndrome: a secondary analysis of randomised controlled trials' (The Lancet Respiratory Medicine, 2020), 'Simvastatin in the Acute Respiratory Distress Syndrome' (New England Journal of Medicine, 2014), 'Subphenotypes in acute respiratory distress syndrome: translation into clinical practice' (The Lancet Respiratory Medicine, 2020), 'Greater recovery after critical illness (GRACE): a call to action to create a new roadmap for critical illness research' (Thorax, 2026), and 'Biofilm communities above and below the cuff of endotracheal tubes are spatially homogenous' (Respiratory Research, 2026). He contributes as a peer reviewer for the New England Journal of Medicine, mentors PhD students, and drives translational research to enhance critical care outcomes.